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Identification of a Unique Subset of 2-Methylene-19-
Nor Analogs of Vitamin D with Comedolytic Activity
in the Rhino Mouse
Nirca J. Nieves1, Jamie M. Ahrens2, Lori A. Plum2, Hector F. DeLuca2 and Margaret Clagett-Dame1,2
The active metabolite of vitamin D, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), and a series of 2-methylene-19-nor
analogs of 1,25(OH)2D3 were evaluated for their ability to reduce the size of utricles (comedolytic activity) in a
rhino mouse model of acne. All analogs tested, as well as the native hormone, increased the skin epidermal
thickness. In contrast, only a subset of analogs that lacked a full side chain and 25-hydroxyl group were found to
possess comedolytic activity. A reduction in comedone area could be achieved without adversely affecting
serum calcium levels. Although all compounds that contained a side chain ranging from 2 to 5 carbons in length
had similar potency as comedolytic agents, increasing the length of the side chain resulted in a progressive
increase in calcemic liability. Dose–response studies of the comedolytic analogs showed that an increase in
epidermal thickness was achieved at a lower dose than that needed to induce comedolysis. Thus, we have
identified a unique subset of vitamin D analogs that produce comedolysis in the absence of hypercalcemia.
Further, the activity of vitamin D analogs in causing epidermal hyperproliferation has been distinguished from
that resulting in a reduction in utricle size.
Journal of Investigative Dermatology (2010) 130, 2359–2367; doi:10.1038/jid.2010.142; published online 10 June 2010
INTRODUCTION
Acne is a disease of the pilosebaceous unit of the skin.
The pathogenesis of this disease involves hyperkeratinization
of the upper region of the follicle, increased sebum
production by the sebaceous gland, colonization of the
follicle by Propionobacterium acnes, and induction of an
inflammatory response. Acne therapy is directed towards
these pathogenic causes with localized topical treatment
used most often, whereas systemic therapy is reserved for the
most severe cases (Gollnick, 2003). Topical treatments
primarily include retinoid therapy, antibiotics, benzoyl
peroxide, and combinations of these agents (Degitz and
Ochsendorf, 2008; Kimball, 2008). These treatments are
all effective at controlling acne but also induce some
unwanted side effects such as photosensitivity and skin
irritation. Alternative topical therapeutic agents for acne that
do not possess these side effects, or have a wider therapeutic
window would be of great advantage for patients with
this condition.
Animal models that simulate a subset of disease
characteristics have been developed, but none of them
recapitulate all aspects of human acne, which is a multi-
faceted condition. The rhino mouse has been useful in
assessing the comedolytic activity of compounds, including
retinoids (Van Scott, 1972; Kligman and Kligman, 1979;
Ashton et al., 1984; Mezick et al., 1984, 1985; Bouclier et al.,
1990, 1991; Bernerd et al., 1991a, b; Zheng et al., 1993; Fort-
Lacoste et al., 1999; Sakuta and Kanayama, 2005; Mirshah-
panah and Maibach, 2007). The rhino (hrrh/hrrh) phenotype is
due to an autosomal recessive mutation in the hairless (hr)
gene. In the rhino mouse, utriculi are derived from the
infundibular zone of the initial follicular units, and are
histologically similar to comedones (Mann, 1971).
The active hormonal form of vitamin D, 1,25-dihydroxy-
vitamin D3 (1,25(OH)2D3), modulates the differentiation and
proliferation of keratinocytes in the skin. In cultured
keratinocytes, 1,25(OH)2D3 induces differentiation and ex-
erts antiproliferative activity (Hosomi et al., 1983; Holick,
1994; Bikle, 2005). This is believed to account for the
positive effects of 1,25(OH)2D3 and analogs in the treatment
of psoriasis. However, topical application of 1,25(OH)2D3
and analogs to normal skin has been shown to induce
keratinocyte proliferation and epidermal hyperplasia, both in
mice (Gniadecki and Serup, 1995; Gniadecki et al., 1995;
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Fujimura et al., 2000) and in humans (Levy et al., 1994).
1,25(OH)2D3 can either stimulate or inhibit DNA synthesis
in cultured human keratinocytes, depending on the composi-
tion of the culture media (Gniadecki, 1996). Thus, the ability
of 1,25(OH)2D3 to promote or inhibit proliferation or
differentiation may depend on the physiological context,
raising the possibility that vitamin D and its analogs could
be useful as therapeutic agents for other disorders of
keratinization. Recently, maxacalcitol, an analog of vitamin
D3 used in the treatment of psoriasis, was evaluated in the
rhino mouse and was found to have comedolytic activity
(Hayashi et al., 2006). This observation suggests that
1,25(OH)2D3 and its analogs may also have utility in the
treatment of comedonal acne.
In addition to its effects on cellular differentiation, the
best-described physiological function of the vitamin D
hormone is to maintain circulating levels of calcium and
phosphorus (Jones et al., 1998). However, the ability of
1,25(OH)2D3 to increase blood calcium level constitutes the
major side effect in the pharmacological use of 1,25(OH)2D3
and its analogs. The recent generation of 19-nor-
1,25(OH)2D3 analogs with modifications in the 2-carbon
position has yielded compounds with physiological selectiv-
ity and in some cases, analogs with lower calcemic activity
(DeLuca et al., 2007). In this study, we examine the activity of
a series of 2-methylene-19-nor analogs of 1a,25-dihydrox-
yvitamin D3 in the skin of the rhino mouse. Herein, we show
that, although all analogs tested induce epidermal thickening,
only a subset exert comedolytic activity.
RESULTS
The ability of 1a,25-dihydroxyvitamin D3 (1,25(OH)2D3) and
a number of structurally modified 2-methylene-19-nor
derivatives of 1,25(OH)2 D3 and D2 to induce comedolysis
and/or epidermal thickening in the rhino mouse was
evaluated as described in Figure 1. Two general groups of
analogs were studied: those containing a full side chain
(containing carbons 20–25; Table 1) and those in which
the side chain was shortened and the 25-hydroxyl group
eliminated. Figure 2a shows the structure of 1,25(OH)2D3
and the structure common to 2-methylene-19-nor analogs.
Previous studies of 19-nor analogs containing a full side chain
revealed a selective activity profile including a higher
potency in inducing cellular differentiation than the parent
hormone. Shortened side chain analogs were also previously
shown to be biologically active in vivo and nearly devoid of
calcemic liability (Plum et al., 2004).
1,25(OH)2D3 does not induce comedolysis
Mice treated with 1,25(OH)2D3 did not show a reduction in
comedone size at either of the two doses tested (6 or
19 nmol kgBW
1 ), compared with vehicle control (Figure 2b–d).
In fact, comedone area was significantly increased in both the
groups receiving 1,25(OH)2D3 (Figure 2e). When the effect of
1,25(OH)2D3 on epidermal thickness was assessed, only a
modest increase (33% above vehicle) was noted at the
19 nmol kgBW
1 dose (Figure 2f) and there was no visual skin
inflammation or influx of inflammatory cells (neutrophils,
data not shown). Animals in both hormone-treated groups
were exposed to drug, as evidenced by a significant increase
in total serum calcium levels (11.6 and 12.0mg per 100ml,
in the 6 and 19 nmol kgBW
1 groups, respectively, compared
with 9.5 and 8.7mg per 100ml in the vehicle groups
(Figure 2g). Thus, 1,25(OH)2D3 was ineffective in inducing
comedolysis and only the highest dose of the native hormone
was able to modestly increase the epidermal thickness.
2-Methylene-19-nor analogs of vitamin D with a full side chain
are not comedolytic
The structure and activities of 19-nor analogs of 1,25(OH)2
D3 and D2 containing a 25-hydroxylated side chain and
modified to contain a methylene group in the 2-carbon
position are shown in Table 1. All of them bind with high
affinity to the vitamin D receptor (VDR) in vitro, activate
transcription, and induce bone calcium mobilization, and
intestinal calcium transport in vivo (Sicinski et al., 2002;
Barycki et al., 2009; see the patent information described in
the section Chemicals under Materials and Methods). The
dose of drug used to test for activity in skin was based on
in vivo potency, with the goal of using a dose that would
produce a 1.0–3.0mg per 100ml increase in serum calcium
level to ensure sufficient drug exposure. For some analogs, a
noncalcemic dose was also examined. After 3 weeks of
treatment, all 2-methylene-19-nor analogs shown in Table 1
were active in increasing epidermal thickness, whereas none
were effective in reducing the comedone area. Epidermal
a
b
Comedone
Figure 1. Comedone area and epidermal thickness determination. Five
images per animal sample were captured. For each image, the (a) area of each
comedone and (b) epidermal thickness were determined with the use of a
Wacom Intuos Tablet linked to the Metamorph Imaging System. Comedone
area measurements were obtained by delineating the perimeter of each utricle
with the tablet; using Metamorph Image Software, an area value for each
individual comedone in pixels was determined. Epidermal thickness
measurements were determined using the distance feature of Metamorph to
determine the thickness of the epidermis at each interfollicular region of the
image. On average, a total of 8–12 measurements of epidermal thickness per
section were collected. Bar¼ 50mm.
2360 Journal of Investigative Dermatology (2010), Volume 130
NJ Nieves et al.
Vitamin D Analogs with Comedolytic Activity
thickness was increased the most (nearly 3 times that of
vehicle) by the highly potent analog, 2-methylene-19-nor-
(20S)-26,27-dimethylene-1a,25(OH)2D3 (CAGE-3); thicken-
ing was observed at a dose of CAGE-3 as low as
0.025 nmol kgBW
1 and was maximal at a 3.2-fold higher dose
(0.079 nmol kgBW
1 ; Supplementary Figure S1 online). An
increase in cellularity in the dermis comprised largely of
mononuclear cells and neutrophils was also noted in
hematoxylin and eosin sections, and a doubling of neutrophil
number occurred at the same dose that produced a significant
increase in epidermal thickness (data not shown). However,
there was no evidence for an increase in the number of
eosinophils when examined by histological staining (Luna) in
the highest CAGE-3-dose group. Interestingly, an increase
in sebaceous remnant area but not number was observed
with increasing doses of the compound starting at
0.079 nmol kgBW
1 (Supplementary Figure S1f online), although
it is not known whether the amount or composition of
sebaceous lipid was altered. The ability of compounds to
increase epidermal thickness was not due to elevated serum
calcium levels, as the analogs 2-methylene-(20R,25S)-19,26-
dinor-1a,25-dihydroxy D3 and CAGE-3 when tested at
noncalcemic doses still produced significant skin thickening
(Table 1; Supplementary Figure S1g online).
2-Methylene-19-nor-(20S)-1a-hydroxybishomopregnacalciferol
(2MbisP) induces both comedolysis and epidermal thickening
As none of the 19-nor analogs with a full side chain showed
comedolytic activity, the ability of 2MbisP, a low-calcemic
19-nor analog that lacks a 25-hydroxyl group and most of the
vitamin D side chain, was tested. Remarkably, 2MbisP not
only increased epidermal thickness but also reduced the size
of comedones in a dose-dependent manner. As shown
in Figure 3, a dose of 69 nmol kgBW
1 was ineffective in
comedolysis, but produced a significant increase in epider-
mal thickness and some neutrophil infiltration (approximately
a fourfold increase in cell number over vehicle; data not
shown). The effect of 2MbisP on epidermal thickening was
Table 1. Biological activity of 19-nor 1,25(OH)2 –D2 and -D3 analogs containing a 25-hydroxylated side chain
Chemical name
Structure
(R group)
Dose
(nmolkgBW
1 )
Comedone
area
(% of vehicle)
Epidermal
thickness
(% of
vehicle)
Serum calcium
(D from
vehicle;
mg per 100ml)
2-Methylene-1a,25-dihydroxy-(17E)-17(20)-dehydro-19-
norvitamin D3 (Vit-III 17–20E)
25 116±15 216*±13 2.0*±0.1
2-Methylene-(20R, 25S)-19,26-dinor-1a,25-dihydroxyvitamin
D3 (NEL)
7.5
25
156±34
147±24
145*±3.7
189*±11
0.1±0.4
1.2*±0.2
2-Methylene-19-nor-(20S)-26,27-dimethylene-1a,25-
dihydroxyvitamin D3 (CAGE-3)
0.025
0.079
158±23
198±63
158*±11
277*±14
0.1±0.3
1.4*±0.4
2-Methylene-18,19-dinor-(20S)-1a,25-dihydroxyvitamin D3
(VD-03)
0.62 90±14 225*±5.9 2.5*±0.2
2-Methylene-19-nor-24-epi-1a,25-dihydroxyvitamin
D2 (20R-2MD-24-epi)
2.3 176±55 189*±13 2.6*±0.2
The activities of compounds in binding to the receptor (kd; nM), and in inducing HL60 cell differentiation (IC50; nM) are as follows: 2-methylene-1a,25-
dihydroxy-(17E)-17(20)-dehydro-19-norvitamin D3 (Vitamin-III 17–20E) (0.4, 20; US 7,241,752 B2); 2-methylene-(20R,25S)-19,26-dinor-1a,25-dihydroxy-
vitamin D3 (NEL) (0.04, 1; US 7,528,122 B2); 2-methylene-19-nor-(20S)-26,27-dimethylene-1a,25-dihydroxyvitamin D3 (CAGE-3) (0.03, 0.04; Sicinski
et al., 2002); 2-methylene-18,19-dinor-(20S)-1a,25-dihydroxyvitamin D3 (VD-03) (0.02, 0.4; Barycki et al., 2009); 2-methylene-19-nor-24-epi-1a,
25-dihydroxyvitamin D2 ((20R)2MD-24-epi) (0.04, 0.1; US 7,232,810 B2). Values for 1,25(OH)2D3 are given for comparison (0.07, 4). Significant differences
from vehicle are indicated by an asterisk, *Po0.05.
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maximal at a dose 0.5 log units higher (218 nmol kgBW
1 ), and
an increase in sebaceous gland area was also seen, but there
was no further increase in neutrophil number. At this dose, a
significant reduction in comedone area was observed (44%),
with a maximal effect observed at 690 nmol kgBW
1 . Higher
doses of compound (up to 2,180 nmol kgBW
1 ) did not improve
the extent of comedolysis, and produced a significant
increase in serum calcium level (2.1±0.2mg per 100ml
above vehicle; data not shown). No redness or swelling of the
skin was noted after 21 days of treatment, although in some
cases exfoliation was evident (data not shown).
The activity of 2MbisP in decreasing comedone area
and increasing epidermal thickness did not change when
compared at 3 and 6 weeks, indicating that the effects
were maximal at the earlier time point (Supplementary
Figure S2 online). Groups treated topically with 2MbisP
(218 nmol kgBW
1 ) for 3 or 6 weeks showed a 43% reduction in
comedone area, as well as a 230% increase in epidermal
thickness compared with the vehicle groups. The ability of
2MbisP to increase epidermal thickness was the result of an
increase in cell proliferation as assessed by an increase in
bromodeoxyuridine incorporation in the basal cell layer as a
result of this treatment (Supplementary Figure S3 online).
The effect of side chain length on activity
In the next experiment, the importance of side chain length to
comedolytic activity was explored in more detail after
3 weeks of topical drug application. 2-methylene-19-nor-
1a-hydroxy-pregnacalciferol (2MPregna) and 2-methylene-
19-nor-1a-hydroxy-homopregnacalciferol (2MP), each with a
further reduction in side chain length compared with 2MbisP
(two and one carbon(s), respectively), as well as a compound
with an additional carbon compared with 2MbisP,
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Figure 2. Activity of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) in rhino
mouse skin. (a) Chemical structure of 1,25(OH)2D3 and the structure of
the A ring of the 2-methylene-19-nor analogs. The effect of topical application
of (b) vehicle, (c) 6 nmol kgBW
1 , or (d) 19 nmol kgBW
1 of 1,25(OH)2D3
on skin morphology. Bar¼ 100mm. (e) Comedone area and (f) epidermal
thickness were measured by image analysis as indicated in the methods
section and Figure 1. (g) Change in total serum calcium level from vehicle
was measured after 21 days of dosing. Dosing solutions were prepared so
that the average mouse (21.3 g) would receive a total of 0.13 or 0.41 nmol
1,25(OH)2D3 for the low and high doses, respectively. Significant differences
from vehicle are indicated by an asterisk, *Po0.05.
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Figure 3. Effect of 2MbisP on comedone area, epidermal thickness, and
serum calcium levels. The effect of topical application of (a) vehicle and (b–d)
2MbisP at 69, 218, and 690nmol kgBW
1 on rhino mouse skin morphology.
Bar¼100 mm. (e) Change in comedone area and (f) epidermal thickness with
increasing doses of 2MbisP. (g) Change in total serum calcium level from
vehicle was measured after 21 days of dosing. Dosing solutions were
prepared so that the average mouse would receive a total of 1.47, 4.64, or
14.9 nmoles at the 69, 218, or 690 nmol kgBW
1 doses, respectively. Significant
differences from vehicle are indicated by an asterisk, *Po0.05.
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2-methylene-19-nor-(20S)-trishomo-1a-hydroxypregnacalciferol
(2MtrisP), were studied. All of the abbreviated side
chain 2-methylene-19-nor analogs, when administered at
690 nmol kgBW
1 , showed significant comedolytic activity
compared with the vehicle control (Figure 4a). At the lower
dose tested (218 nmol kgBW
1 ), all of the analogs, with the
exception of 2MP, produced a slight reduction in comedone
area. All analogs tested also caused a significant increase
in epidermal thickness at both doses (Figure 4b). Although
small changes in the side chain length did not alter
comedolytic activity, increasing the length had a pronounced
effect on the total serum calcium level (Figure 4c). Serum
calcium levels at day 21 remained unchanged for both
2-methylene-19-nor-1a-hydroxy-pregnacalciferol, and 2MP
at each dose, and for 2MbisP at the lower dose. However,
at the highest dose of 2MbisP and both doses of 2MtrisP,
serum calcium levels were significantly increased to above
that of the vehicle group. When the side chain of 2MtrisP
was further extended by two carbons, the comedolytic
potential of the analog could not be tested because of
the severe hypercalcemia that was apparent by day 4 of the
experiment (data not shown). Therefore, 19-nor-1a,25-
(OH)2D3 analogs that significantly reduce the comedone
area at doses that do not cause hypercalcemia were
identified; however, increasing the length of the side
chain increased calcemic liability. Furthermore, this work
shows that a terminal hydroxyl group is not necessary for
2-methylene-19-nor analogs of 1,25(OH)2D3 to show
comedolytic activity.
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Figure 4. 2-Methylene-19-nor analogs of 1,25-dihydroxyvitamin D3
lacking a full side chain possess comedolytic activity. The effect of topical
application of 2-methylene-19-nor-1a-hydroxy-pregnacalciferol (2Mpregna),
2-methylene-19-nor-1a-dihydroxyhomopregnacalciferol (2MP), 2-methylene-
19-nor-(20S)-1a-hydroxybishomopregnacalciferol (2MbisP), and 2-
methylene-19-nor-(20S)-trishomo-1a-hydroxypregnacalciferol (2MtrisP) at
218 and 690nmol kgBW
1 on (a) comedone area, (b) epidermal thickness,
and (c) serum calcium levels after 3 weeks. The low and high doses of
drug were analyzed in two independent experiments. Animals treated with
2MtrisP at 690 nmol kgBW
1 were evaluated after 2 weeks. The response for
each drug at a given dose was compared with the vehicle control group in
that experiment; the data are shown together on the graph. Significant
differences from vehicle are indicated by an asterisk, *P-value o0.05.
Analog structure in Figure 1 with modification to the R group is shown
above the graphs.
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Figure 5. 2-Methylene-19-nor-(20R)-1a-hydroxy-bishomopregna-
calciferol (20R-2MbisP) induces comedolysis. (a) Comedone area and (b)
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2-Methylene-19-nor-(20R)-1a-hydroxy-bishomopregnacalciferol
(20R-2MbisP) is an effective comedolytic agent but is slightly less
potent than the 20S isomer
The importance of the configuration of the methyl group at
carbon 20 within the 2MbisP structure in comedolytic
activity was further explored. At 218 nmol kgBW
1 , 20R-2MbisP
was ineffective in reducing the comedone area (Figure 5),
whereas a higher dose of 690 nmol kgBW
1 was similar in
efficacy to the 218 nmol kgBW
1 dose of 20S-2MbisP (see
Figure 3). Furthermore, 20R-2MbisP was able to produce a
55% reduction in comedone size without an accompanying
increase in serum calcium levels. Thus, the 20R isomer of
2MbisP seemed to be approximately 0.5 log units less active
in comedolytic activity than the 20S configuration. However,
both compounds were efficacious at doses that did not
increase blood calcium levels.
DISCUSSION
From these studies, a specific class of vitamin D analogs that
alters the size and shape of utricles and thickness of the
epidermis in the skin of the rhino mouse in a dose-dependent
manner was identified. Whereas 1,25(OH)2D3 and all 2-
methylene-19-nor analogs tested cause an increase in
epidermal thickness, only those that lack the 25-hydoxyl
group and have a side chain less than five carbons in length
exhibit comedolytic activity.
1,25(OH)2D3 functions by binding to the nuclear VDR,
and this ligand–receptor complex regulates the transcription
of target genes (DeLuca, 2008; Haussler et al., 2008). The
VDR is expressed in a number of cell types in the skin,
including the keratinocyte (Stumpf et al., 1979; Hosomi et al.,
1983; Pillai et al., 1988; Reichrath et al., 1997). All of the
2-methylene-19-nor-1,25(OH)2 D3 and D2 analogs tested
bind with high affinity to the VDR, and have been shown to
be transcriptionally active in reporter cell systems (Sicinski
et al., 2002; Plum et al., 2004; Barycki et al., 2009; see
Table 1 footnote). However, the compounds that are most
effective in inducing comedolysis do not have the highest
affinity to the VDR. Therefore, there is a specificity of action
in comedolysis that cannot be explained merely on the basis
of the binding affinity to the VDR. It is possible that tissue
and/or cell-specific factors present in the skin are responsible
for the ability of some compounds to produce both a
hyperplastic epidermis and a reduction in utricle size.
It has been shown that hormone binding alters the
conformation of the C-terminus of the VDR, creating a
binding surface for the productive interaction with coacti-
vator proteins involved in modulating chromatin structure
and in interacting with the basal transcriptional machinery
(Rochel et al., 2000; Tocchini-Valentini et al., 2001; Vanhooke
et al., 2004, 2007). Multiple coactivator proteins have been
described, and thus it is possible that the shortened side chain
analogs influence the nature of this interaction in a unique
manner.
The VDR has been shown to interact with the hairless gene
(Hsieh et al., 2003). There are some similarities with respect
to defects in hair follicle cycling in VDR knockout and
hairless mutant mice (Li et al., 1997; Yoshizawa et al., 1997;
Zarach et al., 2004); however, it should be noted that the
function of the VDR in this process is independent of the VDR
ligand (Skorija et al., 2005). Cell transfection studies suggest
that Hairless (Hr) may alter the responsiveness of the VDR to
its ligand, but evidence for this in vivo is currently lacking.
Whether the rhino mouse serves as an accurate predictor of
all vitamin D analog-related effects in humans remains to be
established.
The shortened side chain 2-methylene-19-nor analogs
show many similarities to the effects of retinoids in the rhino
model, including hyperproliferation of the epidermis and
reversion of utricles to follicles, or in some cases, their
complete involution (Kligman and Kligman, 1979). It has
been proposed that the ability of retinoids to induce
epidermal proliferation is key to their ability to reduce the
size of the utricle diameter (Ashton et al., 1984). However,
our studies clearly show that vitamin D analogs that increase
the thickness of the epidermis do not always have comedo-
lytic activity. Furthermore, analogs that possess comedolytic
activity induce hyperplasia at doses at which they are not yet
active as comedolytic agents. Only one vitamin D analog has
previously been reported to have comedolytic activity in the
rhino mouse and it was suggested that the resultant
comedolysis was due to an induction of hyperplasia (Hayashi
et al., 2006). Our work supports the conclusion that, at least
for vitamin D analogs, activity in increasing epidermal
proliferation or thickness, per se, is not sufficient to induce
comedolysis.
Vitamin D analogs are used to treat psoriasis and they
cause remission of psoriatic plaques by inhibiting keratinocyte
hyperproliferation and inducing differentiation (Reichrath
et al., 1997). In this study, however, an increase in epidermal
thickness was observed in response to topical application of
all 2-methylene-19-nor analogs. In normal human skin, a
vitamin D analog used in the treatment of psoriasis,
calcipotriol, has been shown to produce a significant
increase in skin thickness after 3 weeks of topical application
in vivo (Levy et al., 1994). In addition to epidermal
thickening, the size of sebaceous gland remnants increased
with the comedolytic compound 2MbisP, as well as with
the noncomedolytic analog CAGE-3. The increase in the
sebaceous area and thickening of the epidermis both seem to
result from increased cell proliferation (Supplementary
Figure S3 online). Interestingly, enlargement of sebaceous
glands was also reported after topical treatment of the
rhino mouse with retinoid (Kligman and Kligman, 1979;
Zheng et al., 1993). In vitro studies on sebaceous gland cells
have shown that 1,25(OH)2D3 exerts a biphasic effect
on sebocyte proliferation that is dependent on dose and
cell culture conditions (Kra¨mer et al., 2009). Thus, the
effect of vitamin D compounds on skin seems to differ
depending on the physiological or pathological state of
the organism at the time of application. This highlights
the potential of vitamin D analogs as treatment for
keratinization disorders such as psoriasis and acne, as well
as in conditions in which an induction of epidermal
thickening is desired, such as adjunct therapy to corticoster-
oid drug use.
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The major limitation in the use of 1,25(OH)2D3 and its
analogs in clinical medicine is the potent effect that these
compounds have on calcium metabolism. Pharmacological
administration of the native hormone by both oral and topical
routes can lead to hypercalcemia (Langner et al., 1993;
Osborn et al., 1995). A recent major advance has been the
development of vitamin D analogs with lesser calcemic
liability. The analogs 2MbisP, 2MP, and 2-methylene-19-
nor-1a-hydroxy-pregnacalciferol given intraperitoneally have
been shown to be very active in inducing the 24-hydroxylase
enzyme in skin and suppressing the secretion of parathyroid
hormone into the bloodstream in vivo, while having very
little effect, if any, on intestinal calcium absorption or
calcium mobilization from bone (Plum et al., 2004; DeLuca
et al., 2007). These compounds, as well as the isomer
20R-2MbisP, also function as comedolytic agents when
applied topically to the rhino mouse at doses that cause no
increase in serum calcium levels. Increasing the vitamin D
side chain up to five carbons in length does not alter the
comedolytic potential of the molecule, but it does cause an
increase in calcemic liability. Thus, efficacy can be obtained
with specific analogs in the absence of perturbing blood
calcium.
In conclusion, we have shown that a subset of
2-methylene-19-nor-1,25(OH)2D3 analogs exert potent co-
medolytic activity in rhino mouse skin, whereas all analogs
tested, as well as the native hormone, increase the epidermal
thickness. Thus, the low-calcemic shortened side chain
2-methylene-19-nor-1,25(OH)2D3 analogs described herein
represent a class of vitamin D analogs with potential for use
in skin disorders including acne.
MATERIALS AND METHODS
Chemicals
1,25(OH)2D3, 2MbisP, 2MP, and 2-methylene-19-nor-1a-hydroxy-
pregnacalciferol were synthesized and purified by SAFC (Madison,
WI, USA) using previously described methods and as modified by
SAFC (Sicinski et al., 1998; Plum et al., 2004). 20R-2MD-24-epi
(DeLuca HF, Sicinski RR, Gowlugari S, inventors; Wisconsin Alumni
Research Foundation Madison, WI, USA assignee. 2-Methylene-19-
nor-Vitamin D Compounds. United States patent US 7,232, 810 B2,
19 June 2007), Vit-III 17-20E (DeLuca HF, Tadi BP, Plum LA, Clagett-
Dame M, inventors; Wisconsin Alumni Research Foundation
Madison, WI, USA assignee. 17,20(E)-dehydro vitamin D analogs
and their uses. United States patent US 7,241,752 B2, 10 July 2007),
2-methylene-(20R,25S)-19,26-dinor-1a,25-dihydroxy D3 (DeLuca
HF, Chiellini G, Gryzwacz P, Plum LA, Clagett-Dame M, inventors;
Wisconsin Alumni Research Foundation Madison, WI, USA assign-
ee. Vitamin D analog-2-methylene-(20R,25S)-19,26-dinor-1a,25-
dihydroxy D3, Methods and uses thereof. United States patent US
7,528,122 B2, 5 May 2009), CAGE-3 (Sicinski et al., 2002), VD-03
(Barycki et al., 2009), 20R-2MbisP (DeLuca HF, Plum LA, Clagett-
Dame M, inventors; Wisconsin Alumni Research Foundation,
Madison, WI, USA assignee. 2-Methylene-19-nor-(20R)-1alpha-
hydroxy-bishomopregnacalciferol. United States patent US 2006/
0135799 A1, 22 June 2006), and 2MtrisP (DeLuca HF, Plum LA,
Clagett-Dame M, inventors; Wisconsin Alumni Research Foundation
Madison, WI, USA assignee. 2-Methylene-19-nor-(20S)-1alpha-
hydroxy-trishomopregnacalciferol. United States patent US 2006/
0135798 A1, 22 June 2006) were prepared as described. The
compounds were determined by HPLC and nuclear magnetic
resonance to be 498% pure.
Compounds were dissolved in ethanol and their concentration
was determined by a UV spectrophotometer using a molar extinction
coefficient of 42,000 at a wavelength of 252 nm for the 2-methylene-
19-nor analogs and 18,200 at 265 nm for 1,25(OH)2D3. Dosing
solutions were prepared in an ethanol:propylene glycol vehicle
(70:30, v/v) so that the dose administered to a 30 g mouse was
delivered in a maximum volume of 100ml.
Animals
All procedures involving animals were reviewed and approved by
the University Committee on Use and Care of Animals at the
University of Wisconsin Madison, WI, USA, which is a facility
accredited by the Association for the Assessment and Accreditation
of Laboratory Animal Care International. Rhino mice (RHJ/LeJ),
heterozygote female (hrrh-J/þ ) and homozygote male (hrrh-J/hrrh-J)
pairs, were obtained from Jackson Laboratory (Bar Harbor, ME).
Homozygote rhino mice (hrrh-J/hrrh-J) were obtained from an in-house
breeding program. Homozygote rhino mice were assigned to study
groups at 6–8 weeks of age, with three males and three females per
group (n¼ 6 per group) with an average weight of 21.3±0.1 g.
Compounds were applied on the entire dorsal (back) area of the
mouse once a day for 21 consecutive days. Animals were weighed
three times per week, and the dose of drug administered was
adjusted weekly on the basis of body weight. Blood was taken
24 hours after the seventh and twenty-first dose by maxillary bleed
for determination of serum calcium levels (see Supplementary
Materials and Methods for details). Skin biopsy samples were
collected 3 days after the last application of compounds.
Skin histology
Skin biopsy samples for histology (approximately 6mm in length)
were laid flat on wooden sticks and fixed overnight in 4%
paraformaldehyde, dehydrated with increasing percentages of
methanol, and embedded in paraffin. Five 10 mm sections were
prepared from each biopsy sample at 150mm intervals. Slices
were stained with Gill’s hematoxylin and eosin, imaged, and
analyzed using MetaMorph Software (Molecular Devices, Down-
ingtown, PA). The area of every comedone in each of five slices was
calculated and the average comedone area was determined for each
mouse. Similarly, epidermal thickness was determined by measuring
the thickness of the epidermis between the comedones
using MetaMorph Software. The area of sebaceous glands was
measured in a similar manner in a subset of experiments. From
these data, mean was determined for the vehicle group and for each
group of animals, the percent of vehicle was determined and
expressed as mean (percent of vehicle)±SEM. The average
comedone area in vehicle-treated mice in these studies was
6615±345mm2 and the thickness of the epidermis was
21.4±0.3mm. Neutrophils were counted in random fields (five per
animal; 400-fold magnification) for the 1,25(OH)2D3
(19 nmol kgBW
1 ), 2MbisP (69, 218, 690 nmol kgBW
1 ) and CAGE-3
(0.0079, 0.025, 0.079, 0.25 nmol kgBW
1 ) dosing groups. Statistical
analysis of variance was performed as described in Supplementary
Materials and Methods.
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